Abeona Therapeutics
New York
About Abeona Therapeutics
Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $429.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:ABEO
- Website: abeonatherapeutics.com
- Phone: (216)287-5408
Industries & Categories
Biotechnology, Genetics, Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/abeona-therapeutics-6296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.